5VT0 Stock Chart & Stats
€30.40
€0.00(0.00%)
At close: 4:00 PM EST
€30.40
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€12.00 - €37.20
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€108.78M
Enterprise Value-€9.31M
Total Cash (Recent Filing)€98.09M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)1594.0
Beta0.42
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.29
Shares Outstanding3,938,654
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)5.23
Price to Sales (P/S)0.00
P/FCF Ratio-13.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€49.70Price Target Upside63.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.22
Revenue Forecast (FY)€24.64M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Stronger CapitalizationVery low debt and materially improved equity reduce financial distress risk and interest burden, giving management structural flexibility to prioritize R&D and partnership negotiations. A cleaner capital structure supports long-term program funding options without heavy leverage constraints.
Late‑stage Phase 3 Catalyst (cadisegliatin)A late‑stage Phase 3 readout is a material, durable value inflection point: positive topline could enable licensing, partnerships or commercialization pathways. This shifts the company from preclinical/early risk to an outcomes‑driven model where trial results materially alter strategic options.
Expanded ATM Program / Financing FlexibilityExpanding ATM capacity provides a persistent mechanism to access public capital opportunistically, smoothing funding for near‑term R&D and the pending Phase 3 readout. Structural financing flexibility reduces reliance on single large raises and supports continuous program execution.
Bears Say
Persistent Negative Cash FlowSustained negative operating and free cash flow evidences ongoing cash burn to fund development. Over months, this forces repeated access to capital markets or partners, raising execution risk if funding conditions deteriorate and limiting ability to self‑fund follow‑on trials or development programs.
Structural Unprofitability And Inconsistent RevenuePersistent operating losses and an uneven revenue record show the company is pipeline‑driven rather than commercially self‑sustaining. TTM net income appears driven by non‑operating items, so core earnings power remains weak and dependent on successful clinical/regulatory outcomes.
Dependence On Equity Financing (dilution Risk)Reliance on ATM equity issuance is a structural funding pathway but creates ongoing dilution risk and overhang. For a clinical‑stage biotech, repeated equity raises can compress long‑term returns for shareholders and complicate partner negotiations if perceived as inevitable to fund operations.
vTv Therapeutics News
5VT0 FAQ
What was vTv Therapeutics’s price range in the past 12 months?
vTv Therapeutics lowest stock price was €12.00 and its highest was €37.20 in the past 12 months.
What is vTv Therapeutics’s market cap?
vTv Therapeutics’s market cap is €108.78M.
When is vTv Therapeutics’s upcoming earnings report date?
vTv Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 112 days.
How were vTv Therapeutics’s earnings last quarter?
vTv Therapeutics released its earnings results on May 13, 2026. The company reported €1.443 earnings per share for the quarter, beating the consensus estimate of €0.184 by €1.259.
Is vTv Therapeutics overvalued?
According to Wall Street analysts vTv Therapeutics’s price is currently Undervalued.
Does vTv Therapeutics pay dividends?
vTv Therapeutics does not currently pay dividends.
What is vTv Therapeutics’s EPS estimate?
vTv Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does vTv Therapeutics have?
vTv Therapeutics has 3,938,654 shares outstanding.
What happened to vTv Therapeutics’s price movement after its last earnings report?
vTv Therapeutics reported an EPS of €1.443 in its last earnings report, beating expectations of €0.184. Following the earnings report the stock price went down -1.493%.
Which hedge fund is a major shareholder of vTv Therapeutics?
Currently, no hedge funds are holding shares in DE:5VT0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
vTv Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€49.70 (63.50% Upside)
€49.70 (63.50% Upside)
Blogger Sentiment
Bullish
DE:5VT0 Sentiment 100%
Sector Average 67%
Sector Average 67%
Technicals
SMA
Positive
20 days / 200 days
Momentum
45.75%
12-Months-Change
Fundamentals
Return on Equity
3.96%
Trailing 12-Months
Asset Growth
208.53%
Trailing 12-Months
Company Description
vTv Therapeutics
vTv Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on creating orally administered treatments, with a significant emphasis on diabetes. Its pipeline features lead candidates such as TTP399, an oral, small-molecule, liver-specific glucokinase activator targeting Type 1 diabetes. Another key investigational drug is HPP737, an oral phosphodiesterase type 4 (PDE4) inhibitor that does not cross the blood-brain barrier (non-CNS penetrant), designed to treat inflammatory conditions and psoriasis. Beyond these, vTv Therapeutics' broader clinical portfolio includes: TTP273, an oral small-molecule GLP-1 receptor agonist addressing postprandial glucose excursions in cystic fibrosis-related diabetes. HPP3033, which employs a non-electrophilic strategy to activate the Nrf2 pathway for chronic conditions linked to oxidative stress. Azeliragon, a RAGE antagonist being evaluated for inflammatory lung disorders, notably severe COVID-19, alongside pancreatic and breast cancers. HPP971, an Nrf2 activator aimed at renal diseases, developed in collaboration with pharmaceutical partners. Furthermore, vTv holds a licensing agreement with Reneo Pharmaceuticals, Inc. for the development and commercialization of its peroxisome proliferation-activated receptor delta agonist program, which features the compound HPP593. The company has also established various other licensing and research collaborations with entities such as Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Newsoara Biopharma Co., Ltd., JDRF International, and Novo Nordisk A/S. Established in 2015, vTv Therapeutics is headquartered in High Point, North Carolina, and operates as a subsidiary of MacAndrews & Forbes Incorporated.
5VT0 Stock 12 Month Forecast
Average Price Target
€49.70
▲(63.50% Upside)